PROTAC Assays Service

Proteolysis Targeting Chimera (PROTAC) is an emerging targeted protein degradation technology. Its fundamental principle involves using small molecule compounds to link the target protein with an E3 ligase, facilitating the ubiquitination of the target protein, which is then recognized and degraded by the proteasome. PROTAC technology enables the selective degradation of target proteins in cells, overcoming the limitations of traditional small-molecule drugs that can only inhibit protein function. Additionally, it regulates protein levels in organisms through targeted protein degradation, demonstrating significant application potential.

PROTAC assays service is widely applied in the fields of cancer, neurodegenerative diseases, and immune disorders. By targeting and degrading oncogenic proteins in cancer or aberrant proteins in neurodegenerative diseases, PROTAC provides new strategies for targeted therapy and disease research. Moreover, PROTAC has important applications in drug development and antibody drug discovery, positioning itself as a cutting-edge technology in pharmaceutical research.

Dale, B. et al. Nature reviews Cancer, 2021.

Figure 1. Mechanism of PROTAC-Mediated Target Protein Degradation.

Services at MtoZ Biolabs

Leveraging advanced mass spectrometry analysis technology, MtoZ Biolabs provides PROTAC assays service that can accurately and reliably analyze proteins, aiming to help scientific researchers explore and study the mechanisms of targeted protein degradation and their potential drug development applications.

Service Advantages

1. Advanced Analysis Platform

MtoZ Biolabs established an advanced PROTAC assays service platform, guaranteeing reliable, fast, and highly accurate analysis service.

2. One-Time-Charge

Our pricing is transparent, no hidden fees or additional costs.

3. High-Data-Quality

Deep data coverage with strict data quality control. AI-powered bioinformatics platform integrates all proteomics analysis data, providing clients with a comprehensive data report.

4. Customized Services

We offer personalized PROTAC design and synthesis services tailored to the research objectives of our clients, meeting diverse scientific needs.

Applications

1. Drug Development and Clinical Applications

PROTAC assays service enables targeted protein degradation, overcoming the limitations of traditional small-molecule drug mechanisms and providing new directions for drug discovery. Particularly in the treatment of cancer and neurodegenerative diseases, PROTAC offers novel targets and approaches for precision therapy.

2. Protein Function Research

By utilizing specific PROTAC molecules, researchers can rapidly and accurately investigate the biological functions and mechanisms of target proteins, providing strong support for fundamental research.

3. Antibody Drug Development

PROTAC assays service can be used to target the degradation of proteins involved in immune responses, optimizing the development of antibody drugs. By selectively degrading immune-related proteins, PROTAC technology has the potential to enhance therapeutic efficacy.

4. Cancer Research

The application of PROTAC technology in cancer treatment has gained increasing attention. By targeting and degrading pathogenic proteins in cancer cells, PROTAC provides new approaches for personalized cancer therapy.

5. Neurodegenerative Diseases

In the study of neurodegenerative diseases such as Alzheimer's and Parkinson's disease, PROTAC technology can degrade abnormal proteins (e.g., Tau protein, α-synuclein), offering promising new therapeutic strategies.

Case Study

1. PROTAC-mediated FTO protein degradation effectively alleviates diet-induced obesity and hepatic steatosis

This study primarily investigates the effects of PROTAC (Proteolysis Targeting Chimera)-mediated degradation of Fat Mass and Obesity-Associated Protein (FTO) in alleviating diet-induced obesity and hepatic steatosis. The findings demonstrate that selective degradation of FTO protein via PROTAC technology can effectively reduce obesity and liver fat accumulation caused by a high-fat diet. Furthermore, the study validates the role of FTO in metabolic diseases and highlights the potential of PROTAC-mediated protein degradation as a novel therapeutic strategy for metabolic disorders. Experimental results indicate that FTO degradation improves insulin sensitivity, reduces hepatic lipid accumulation, and mitigates obesity-related metabolic dysfunctions. This research provides a theoretical foundation for the development of new therapeutic drugs targeting obesity, non-alcoholic fatty liver disease (NAFLD), and other metabolic diseases.

Yang, X. et al. International Journal of Biological Macromolecules, 2024.

Figure 2. PROTAC-Mediated FTO Protein Degradation Analysis.

Deliverables

1. Comprehensive Experimental Details

2. Materials, Instruments, and Methods

3. Data Analysis, Preprocessing, and Estimation 

4. Bioinformatics Analysis

5. Raw Data Files

MtoZ Biolabs, an integrated Chromatography and Mass Spectrometry (MS) Services Provider, provides advanced proteomics, metabolomics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. Our ultimate aim is to provide more rapid, high-throughput, and cost-effective analysis, with exceptional data quality and minimal sample consumption. Free project evaluation, welcome to learn more details!